NCT04820907View on ClinicalTrials.gov

Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Hypertension
Interventions
DRUG

HCP1904-1

Take it once daily for 8 weeks orally.

DRUG

RLD2001-1

Take it once daily for 8 weeks orally.

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT04820907 - Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients | Biotech Hunter | Biotech Hunter